Currentblue cross blue shield - tennesseePolicy N/A

Intracellular Micronutrient Analysis

This policy governs coverage and limitations for intracellular micronutrient testing (proprietary panels and assays measuring intracellular vitamin/mineral levels) for Blue Cross Blue Shield - Tennessee members.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyIntracellular Micronutrient Analysis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDo not request prior authorization for intracellular micronutrient panels because they do not meet coverage criteria; submit claims using the listed CPT/unlisted codes if reporting individual analytes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance summarized

Not clearedFDA status

CLIA LDTsLDT / CLIA

>25 codesBilling codes

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered — Intracellular micronutrient panels: Intracellular micronutrient panel testing (e.g., SpectraCell, Cell Science Systems Cellular Micronutrient Assay, ExaTest) does not meet coverage criteria due to a lack of published scientific literature demonstrating accuracy, clinical utility, or benefit for diagnosis or treatment.

No controlled studies showing impact on patient management or health outcomes and no practice guideline recommendations were identified.

No recommendations or professional practice guidelines supporting the clinical use of intracellular micronutrient testing were identified in the literature search conducted for this policy. Specifically, the review found no studies that evaluate the accuracy or clinical utility of intracellular micronutrient measurements compared to standard serum testing, and no controlled studies demonstrating changes in patient management or health outcomes resulting from these tests.

The tests discussed in this policy — including SpectraCell's micronutrient panel, IntraCellular Diagnostics ExaTest, Genova Diagnostics NutrEval FMV, and the Cell Science Systems Cellular Micronutrient Assay (CMA) — are offered by CLIA‑accredited laboratories as laboratory‑developed tests (LDTs). These specific proprietary panels have not been through the FDA approval process and are not FDA‑cleared or approved.

Intracellular micronutrient panel testing is considered not medically necessary and does not meet coverage criteria because the evidence base is insufficient. The policy review did not identify adequate published scientific literature demonstrating test accuracy or clinical utility versus standard serum testing, nor controlled studies showing benefit to patient management or health outcomes; limited correlation data between serum and intracellular measures were available and intracellular methods were not included in published reviews or guideline recommendations.

Covered Indications / Available Tests

Serum nutrient testing vs Intracellular panels

Available serum testing is the standard approach; intracellular panels lack supportive evidence and are not supported for coverage.

Preferred and available tests: Serum vitamin and mineral (nutrient) testing is widely available and is the commonly used, standard approach for assessing nutrient status.

Serum measurements vary by nutrient and can be influenced by recent intake, illness, and tissue distribution.

Intracellular panels — evidence and regulatory status: Intracellular micronutrient testing (measuring intracellular concentrations) has limited data correlating with serum levels and lacks identified studies demonstrating accuracy or clinical utility compared to standard serum testing.

Many intracellular/proprietary tests are offered as laboratory-developed tests (LDTs) under CLIA; they have not undergone FDA approval/clearance.

Proprietary vendors and tests (no covered indications specified)

The document names several commercial tests and laboratories but does not assert covered clinical indications for these proprietary panels.

Vendor/test listing: The policy references companies and proprietary tests including SpectraCell, IntraCellular Diagnostics ExaTest, Genova Diagnostics NutrEval FMV, and Cell Science Systems Cellular Micronutrient Assay (CMA).

These tests are described as being offered by CLIA‑accredited laboratories and many are laboratory‑developed tests not reviewed by the FDA.

Coverage implications: Listing of these vendors/tests in the document does not constitute an endorsement or establishment of covered clinical indications; intracellular micronutrient panel testing is specified elsewhere in the policy as not meeting coverage criteria.

Coverage determination is dependent on the individual's benefit and applicable state/federal regulations.

Not Covered Procedures

Intracellular micronutrient panel testing (for example, SpectraCell micronutrient panel, Cell Science Systems Cellular Micronutrient Assay, and ExaTest) does not meet coverage criteria and is therefore not covered under this policy.

The proprietary tests referenced in this policy are laboratory‑developed tests performed in CLIA‑accredited laboratories and have not been approved or cleared by the FDA. Because these assays are LDTs without FDA clearance, the policy does not consider them to meet coverage criteria.

Reimbursement / Billing Codes

Reimbursement CPT/chemistry codes referencedCPT

82128	Amino acids; multiple, qualitative, each specimen
82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
82180	Ascorbic acid (vitamin c), blood
82310	Calcium; total
82379	Carnitine (total and free), quantitative each specimen
82495	Chromium
82525	Copper
82607	Cyanocobalamin (Vitamin B-12)
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
82725	Fatty acids, nonesterified

1–10 of 26

1/3

Provider Actions and Billing Guidance

Prior Authorization

Prior Authorization Not Supported

Prior authorization is not supported for intracellular micronutrient panel testing. These tests (for example, SpectraCell, Cell Science Systems, ExaTest) DO NOT MEET COVERAGE CRITERIA and may be denied if submitted for coverage.

Intracellular micronutrient panel testing (SpectraCell, Cell Science Systems, ExaTest) is non-covered

Billing Rule

Use Listed CPT Codes for Claims

When submitting claims for micronutrient testing, use the listed CPT codes where appropriate. If a specific analyte is not listed, bill using CPT 84999 (Unlisted chemistry procedure) with appropriate documentation of the test performed.

Covered/acceptable CPT examples: 82128, 82136, 82180, 82310, 82379, 82495, 82525, 82607, 82652, 82725, 82746, 82978, 83735, 83785, 84207, 84252, 84255, 84425, 84446, 84590, 84591, 84597, 84630, 84999, 86353, 88348

Note

Preferred Testing Method

Serum nutrient testing is the standard and preferred method for assessing nutrient status. Intracellular testing is presented in the literature as an alternative approach but lacks sufficient evidence to support coverage.

Preferred testing approach: serum nutrient testing; intracellular testing is unsupported

Documentation Required

Laboratory Identification and Test Documentation Required

Identify the performing laboratory and the specific test on all documentation and claim submissions. For laboratory-developed tests (LDTs) or tests not FDA-cleared, include the lab name, test name, and any supporting validation or methodology notes to aid review.

Include performing laboratory name and CLIA status when available
Document specific test name and methodology (e.g., LDT, panel components)
Provide validation or supporting documentation for non-FDA-cleared tests

Note

Coverage Determination Dependencies

Coverage determinations depend on the member's benefit plan and may be superseded by applicable Medicare or Medicaid (LCD/NCD) policies. If a government policy conflicts with this policy, the government policy will govern the coverage decision.

Coverage depends on member benefits
Medicare/Medicaid LCDs/NCDs and state Medicaid rules may supersede this policy

Denial Risk

Denied Tests — Denial Risk

Intracellular micronutrient panel tests (examples: SpectraCell micronutrient panel, IntraCellular Diagnostics ExaTest, Genova NutrEval FMV, Cell Science Systems CMA) carry a high denial risk because they do not meet coverage criteria.

Examples of tests at risk for denial: SpectraCell micronutrient panel, IntraCellular Diagnostics ExaTest, Genova NutrEval FMV, Cell Science Systems Cellular Micronutrient Assay (CMA)

Denial Risk

Government Policy Supersedes When Conflicting

If a government policy (e.g., LCD or NCD) conflicts with this policy, claims may be denied in accordance with that government policy. Verify and follow the most current Medicare and state Medicaid guidance where applicable.

Government policies (LCDs/NCDs) supersede this policy when applicable
Check CMS and state Medicaid sites for up-to-date coverage guidance: http://www.cms.gov/medicarecoverage-database/search.aspx

Ordering Requirements and Provider Restrictions

Step Therapy

Ordering: benefits-dependent; tests are LDTs offered by CLIA labs

Coverage for the intracellular tests described is dependent on the member's benefit coverage; the tests are offered by CLIA-accredited laboratories and are generally laboratory-developed tests not reviewed by FDA.

Tests described are LDTs regulated under CLIA as high-complexity tests.
Verify member benefits and applicable state/federal regulations before ordering.

Note

No ordering-provider restrictions specified

No explicit restrictions on who may order these tests are stated in the policy.

Definitions

CMA (Cellular Micronutrient Assay) — definition and reporting metric

TermCellular Micronutrient Assay (CMA)

DefinitionAn assay measuring lymphocyte proliferation response to added micronutrients, reported as stimulation index (SI).

Associated CPT-like procedure86353 (Lymphocyte transformation, mitogen or antigen induced) — used to capture lymphocyte proliferation testing in reimbursement section.

ASEM / EXA — analytical methods

TermASEM / EXA

DefinitionASEM = Analytical Scanning Electron Microscopy; EXA = Energy Dispersive X‑Ray Analysis — analytical methods used to analyze elemental composition of epithelial cells for some proprietary intracellular tests (e.g., ExaTest).

Example useExaTest uses buccal epithelial cell swabs analyzed by ASEM and EXA to report tissue evaluations of minerals and electrolytes.

Laboratory-developed test (LDT) — CLIA regulation and FDA status

TermLaboratory-developed test (LDT)

DefinitionA test developed and validated within a single laboratory and performed in‑house; regulated by CMS under CLIA as a high‑complexity test and not approved or cleared by the U.S. Food and Drug Administration.

Regulatory noteLDTs are subject to CLIA '88 requirements; FDA clearance or approval is not currently required for clinical use but LDTs are not FDA‑approved or cleared.

Background

Micronutrients — vitamins and trace elements — are essential dietary components required for normal metabolic processes. Measurement of nutrient status is commonly performed using serum nutrient concentrations, which are widely available from commercial laboratories. Serum levels can vary by nutrient and be influenced by recent intake, acute illness, or tissue distribution; intracellular measurements (for example, lymphocyte‑based assays) have been proposed to reflect longer‑term or tissue‑level status, but the evidence supporting their clinical use is limited.

Frequency Limits

FREQUENCY LIMITS — general note

Frequency limits providedNone specified in this policy for intracellular micronutrient testing.

Typical period fieldNot applicable — policy does not list test-specific repeat intervals.

Action for billingUse listed CPT/chemistry codes when submitting claims; frequency rules are not defined here.

FREQUENCY LIMITS — coding and billing note

Reimbursement codes referencePolicy lists specific CPT/chemistry codes for micronutrient and related testing (see coding section).

No frequency constraintsNo numeric limits or time intervals are provided for these codes in the policy.

Billing instructionWhen submitting claims, use the CPT codes listed in the reimbursement section (e.g., 82128, 82136, 82180, 82310, 86353, 88348, etc.).

Policy Summary

Payerblue cross blue shield - tennessee

PolicyIntracellular Micronutrient Analysis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page